The success of BoneOscopy relies on the interdisciplinarity of its consortium, which comprises institutions with key expertise in multiple disciplines such as bioengineering, biology, physics, instrumentation, robotics and clinical PRT. If achieved, the proposed science-to-technology breakthrough will have a transformative impact on current cancer treatment by providing a safe, personalised and quantitative measure of daily treatment efficacy, thereby contributing to the global fight against cancer.
The BoneOscopy project has received funding from the European Union’s Horizon Europe research and innovation programme under the Grant Agreement N 101185141, and for the Swiss partner from the Swiss State Secretariat for Education, Research and Innovation (SERI). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.
Contact us
Copyright © 2025 | accelopment Schweiz AG | All Rights Reserved · Read our Privacy Policy.